DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,370,254 | +2.5% | 70,013 | -0.8% | 3.55% | +5.8% |
| Q2 2023 | $16,947,148 | -25.3% | 70,613 | -21.6% | 3.36% | -7.0% |
| Q1 2023 | $22,686,318 | -4.8% | 90,011 | +0.3% | 3.61% | -9.8% |
| Q4 2022 | $23,830,412 | +2.6% | 89,784 | -0.2% | 4.00% | -7.6% |
| Q3 2022 | $23,225,000 | +0.3% | 89,919 | -1.5% | 4.33% | +6.8% |
| Q2 2022 | $23,155,000 | -14.8% | 91,334 | -1.4% | 4.05% | +1.3% |
| Q1 2022 | $27,183,000 | -11.4% | 92,670 | -0.6% | 4.00% | -0.5% |
| Q4 2021 | $30,676,000 | +3.0% | 93,236 | -4.7% | 4.02% | -3.8% |
| Q3 2021 | $29,786,000 | -4.4% | 97,838 | -15.7% | 4.18% | -2.8% |
| Q2 2021 | $31,162,000 | +19.7% | 116,121 | +0.4% | 4.30% | +13.9% |
| Q1 2021 | $26,030,000 | +1.1% | 115,649 | -0.2% | 3.77% | -2.8% |
| Q4 2020 | $25,749,000 | +3.2% | 115,911 | +0.0% | 3.88% | -8.5% |
| Q3 2020 | $24,949,000 | +4.8% | 115,862 | -13.9% | 4.24% | -1.2% |
| Q2 2020 | $23,799,000 | +23.6% | 134,585 | -3.3% | 4.30% | +2.9% |
| Q1 2020 | $19,255,000 | -11.1% | 139,114 | -1.4% | 4.17% | +13.2% |
| Q4 2019 | $21,660,000 | +6.3% | 141,127 | +0.1% | 3.69% | -0.9% |
| Q3 2019 | $20,368,000 | +0.4% | 141,021 | -0.6% | 3.72% | +0.1% |
| Q2 2019 | $20,281,000 | -8.9% | 141,903 | -15.8% | 3.72% | -12.0% |
| Q1 2019 | $22,261,000 | +28.8% | 168,618 | +0.6% | 4.23% | +10.8% |
| Q4 2018 | $17,277,000 | -11.9% | 167,539 | -7.2% | 3.82% | +14.3% |
| Q3 2018 | $19,612,000 | +6.3% | 180,485 | -3.5% | 3.34% | +4.8% |
| Q2 2018 | $18,451,000 | -0.4% | 186,979 | -1.2% | 3.18% | +0.3% |
| Q1 2018 | $18,523,000 | +3.9% | 189,187 | -1.5% | 3.18% | +5.3% |
| Q4 2017 | $17,826,000 | +3.0% | 192,047 | -4.8% | 3.02% | +3.3% |
| Q3 2017 | $17,301,000 | +0.5% | 201,689 | -1.2% | 2.92% | -2.8% |
| Q2 2017 | $17,223,000 | -12.4% | 204,083 | -11.3% | 3.00% | -15.1% |
| Q1 2017 | $19,669,000 | +10.2% | 229,966 | +0.3% | 3.54% | +5.0% |
| Q4 2016 | $17,852,000 | -1.8% | 229,340 | -1.1% | 3.37% | -2.7% |
| Q3 2016 | $18,185,000 | -22.5% | 231,986 | -0.1% | 3.46% | -25.0% |
| Q2 2016 | $23,462,000 | +4.1% | 232,295 | -2.3% | 4.62% | +6.4% |
| Q1 2016 | $22,543,000 | +0.8% | 237,648 | -1.3% | 4.34% | +0.6% |
| Q4 2015 | $22,374,000 | +8.2% | 240,896 | -0.7% | 4.31% | +4.6% |
| Q3 2015 | $20,680,000 | -0.0% | 242,696 | +0.4% | 4.12% | +9.4% |
| Q2 2015 | $20,688,000 | +1.4% | 241,712 | +0.6% | 3.77% | -0.4% |
| Q1 2015 | $20,409,000 | -0.4% | 240,388 | +0.6% | 3.78% | -3.2% |
| Q4 2014 | $20,481,000 | +12.1% | 238,956 | -0.6% | 3.91% | +6.7% |
| Q3 2014 | $18,264,000 | -4.2% | 240,373 | -0.7% | 3.66% | -4.5% |
| Q2 2014 | $19,061,000 | +5.7% | 242,107 | +0.7% | 3.83% | +0.3% |
| Q1 2014 | $18,031,000 | -0.8% | 240,412 | +2.1% | 3.82% | -1.4% |
| Q4 2013 | $18,184,000 | +12.9% | 235,549 | +1.4% | 3.88% | +2.1% |
| Q3 2013 | $16,100,000 | +9.8% | 232,254 | +0.3% | 3.80% | +3.1% |
| Q2 2013 | $14,663,000 | – | 231,645 | – | 3.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |